Hyperfractioned Regional Nodal Irradiation for women with invasive breast cancer

Trial ID:
IRB-22-7881
Ray Lin, M.D.
This study will test the safety and effectiveness of regional-nodal irradiation given over 3 weeks compared to the standard of 5 weeks.

Inclusion Criteria

Patients must:

  • Be 18 years or older
    Have pathologically confirmed invasive breast cancer
    Prior mastectomy or lumpectomy with axillary evaluation

Exclusion Criteria

Patients must not:

  • Have clinical or pathological evidence of metastases
    Have cancer diagnosed in both breasts
    Have had previous irradiation to breast, neck, or chest

Additional Info

Radiation treatments will be performed at Prebys Cancer Center in Hillcrest and Scripps MD Anderson Cancer Center in La Jolla.

Each participant will be followed for 10 years and will be expected to complete a series of questionnaires at certain time points.

For more information, search for NCT02912312 at www.clinicaltrials.gov

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org